Metabolism Assays Market

Metabolism Assays Market Size by Product (Instruments, Assays Kits), Technology (Colorimetry, Fluorimetry, Spectrometry), Application (Diagnostics (Diabetes, Obesity), Research), End User (Hospitals, Diagnostic Laboratories), & Region - Global Forecast to 2028

Report Code: MD 8799 Sep, 2023, by marketsandmarkets.com

The global size of metabolism assays market in terms of revenue was estimated to be worth $1.4 billion in 2023 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The growth in this market is attributed to the growing prevalence of diabetes, the global increase in the number of hospitals, and the high rate of obese population. However, alternative methods or techniques restrain the growth of this market.

Attractive Opportunities in the Metabolism Assays Market

Metabolism Assays Market

To know about the assumptions considered for the study, Request for Free Sample Report

Metabolism Assays Market

Metabolism Assays Market Dynamics

DRIVER: Increasing funding and investments in metabolic research

Metabolic research funding and investments are crucial for advancing the metabolic processes understanding, producing new metabolic disease treatments, and improving public health. Diseases like diabetes, obesity, lipid metabolism, mitochondrial disorders, and metabolic pathways are being considered as metabolic diseases. Various sources, including government agencies, private foundations, pharmaceutical companies, and academic institutions are the sources for funding. For instance, clinical-stage biotechnology firm Eccogene raised USD 25.23m (CNY180m) in a Series B financing round to support the development of its clinical-stage metabolic pipeline, in June 2023.

RESTRAINTS: High cost of metabolism assay analyzers

The adoption of metabolism assays can be hindered due to the high costs, especially with limited budgeted facilities like smaller research laboratories or healthcare facilities. To mitigate these costs, the organizations may explore options like group purchasing, leasing or financing agreements, and collaborations with larger institutions. There is the development of more cost-effective analyzers or alternative testing methods that reduce expenses while maintaining accuracy and reliability, as technology advances and competition increases. For instance, the Seahorse Xfe 96 Cell Analyzer System and Seahorse XF HS Mini Analyzer by Agilent Technologies, Inc. (US) cost USD 189,612 and USD 68,611, respectively.

OPPORTUNITY: Integration with wearable devices

The overall health monitoring and management experience for individuals can be enhanced by integrating metabolism assay data with digital health platforms, apps, and wearable devices. For instance, Sweat-based wearable technologies have great potential to collect important data on biomarkers which are related to metabolic syndrome and its associated diseases. These wearable devices can measure glucose, CRP, cortisol, and sodium levels, making them invaluable for patients at risk of developing diabetes and cardiovascular diseases.

CHALLENGE: Complexity of assay development

Due to the intricate nature of metabolic pathways and the need for precise measurement techniques, it can be complex and time-consuming to develop accurate and reliable metabolism assays. Ensuring consistency and reproducibility across different experiments and laboratories can be a challenge. A multidisciplinary approach is required for these complexities which involves expertise in biochemistry, cell biology, molecular biology, analytical chemistry, and computational biology.

Metabolism Assays Market Ecosystem

Prominent companies in this market include well-established, financially stable manufacturers of metabolism assays. These companies have been operating in the market for several years and possess diversified state-of-the-art technologies, strong global sales and product portfolios, and marketing networks. Prominent companies in this market include Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US).

Metabolism Assays Market Ecosystem

In 2022, assay kits & reagents segment to observe the highest growth rate of the metabolism assays industry, by product.

Based on product, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share can be attributed to features like availability and integration with other technologies like wearable devices.

In 2022, colorimetry segment to dominate the metabolism assays industry, by technology.

Based on technology, the metabolism assays market is segmented into colorimetry, fluorimetry, and spectrometry. The colorimetry segment accounted for the largest share of the market in 2022. Also, this segment is estimated to witness the highest growth during the forecast period. The large share is due to well-established method for measuring metabolites and biomarkers in a wide range of biological samples and large use in industrial settings to assess metabolic parameters and provide valuable data for various applications, including disease diagnosis and drug development.

In 2022, North America to dominate in metabolism assays industry.

The global metabolism assays market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is expected to dominate during the forecast period, primarily due to the sedentary work life which will lead to obesity & diabetes, and large population consuming junk food causing obesity. However, during the forecast period, Asia Pacific is expected to register highest CAGR. The factors contributing to the growth of Asia Pacific are large patient pool, growing number of local players, increasing awareness, and rise in disease research fundings by the government.

Metabolism Assays Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The metabolism assays market is dominated by players such as Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US).

Scope of the Metabolism Assays Industry:

Report Metric

Details

Market Revenue in 2023

$1.4 billion

Estimated Value by 2028

$2.1 billion

Revenue Rate

Poised to grow at a CAGR of 7.8%

Market Driver

Increasing funding and investments in metabolic research

Market Opportunity

Integration with wearable devices

This research report categorizes the Metabolism assays market to forecast revenue and analyze trends in each of the following submarkets:

By Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

By Product

  • Instruments & Analyzers
  • Assay Kits & Reagents

By Technology

  • Colorimetry
  • Fluorimetry
  • Spectrometry

By Application

  • Diagnostics
  • Research

By End User

  • Hospitals
  • Diagnostics Laboratories
  • Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes  

Recent Developments of Metabolism Assays Industry

  • In 2022, Thermo Fisher Scientific, Inc. (US) collaborated with Symphogen (Denmark) and Servier (France) for biopharmaceutical discovery and development laboratories.
  • In 2021, Abcam Plc. (UK) acquired BioVision (UK). This acquisition of BioVision represents a compelling strategic fit for Abcam. This will bring greater control over the innovation and distribution of BioVision’s product portfolio and create value through portfolio expansion and leveraging Abcam’s global channels to market.
  • In 2021, Agilent Technologies Inc. (US) launched Agilent Seahorse XF HS Miniplate which is the latest addition to Agilent’s range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 24)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
          TABLE 1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
    1.6 LIMITATIONS 
 
2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH DATA 
          FIGURE 1 METABOLISM ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    TABLE 2 KEY DATA FROM PRIMARY SOURCES
                    FIGURE 2 KEY INDUSTRY INSIGHTS
                    2.1.2.1 Breakdown of primary interviews
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 5 BOTTOM-UP APPROACH: REVENUE-BASED APPROACH
           2.2.1 GROWTH FORECAST
           2.2.2 CAGR PROJECTIONS
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.2.3 TOP-DOWN APPROACH
                    FIGURE 7 METABOLISM ASSAYS INDUSTRY: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE/RANKING ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ASSESSMENT 
    2.7 IMPACT OF RECESSION 
 
3 EXECUTIVE SUMMARY (Page No. - 40)
    FIGURE 9 METABOLISM ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
    FIGURE 10 METABOLISM ASSAYS INDUSTRY, BY TECHNOLOGY,  2023 VS. 2028 (USD BILLION)
    FIGURE 11 MARKET, BY APPLICATION,  2023 VS. 2028 (USD BILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    FIGURE 13 REGIONAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 45)
    4.1 MARKET OVERVIEW 
          FIGURE 14 INCREASED PREVALENCE OF OBESITY AND DIABETES TO DRIVE METABOLISM ASSAYS INDUSTRY
    4.2 ASIA PACIFIC: MARKET,  BY PRODUCT (2022) 
          FIGURE 15 ASSAY KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE IN 2022
    4.3 REGIONAL GROWTH OPPORTUNITIES IN MARKET 
          FIGURE 16 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
    4.4 MARKET: REGIONAL MIX 
          FIGURE 17 ASIA PACIFIC MARKET TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD
    4.5 MARKET:  DEVELOPED VS. EMERGING ECONOMIES 
          FIGURE 18 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 49)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN METABOLISM ASSAYS MARKET
           5.2.1 DRIVERS
                    5.2.1.1 Increasing funding and investments in metabolic research
                    5.2.1.2 Drug discovery and development
                    5.2.1.3 Rise in prevalence of chronic diseases
                    5.2.1.4 Increased use of metabolism assays in fitness and sports
                    5.2.1.5 Growing demand for personalized medicines
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of metabolism assay analyzers
                    5.2.2.2 Presence of alternative methods and techniques
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Integration with wearable devices
                    5.2.3.2 Growing life science research in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Complexity of assay development
    5.3 PRICING ANALYSIS 
          TABLE 3 AVERAGE SELLING PRICE OF PRODUCT, BY KEY PLAYERS
    5.4 PATENT ANALYSIS 
          FIGURE 20 PATENT ANALYSIS FOR METABOLISM ASSAYS  (JANUARY 2013–DECEMBER 2022)
           5.4.1 LIST OF KEY PATENTS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 22 MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 23 MARKET: ECOSYSTEM ANALYSIS
           5.7.1 MARKET: ROLE IN ECOSYSTEM
                    FIGURE 24 KEY PLAYERS IN MARKET
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 4 PORTER’S FIVE FORCES ANALYSIS: MARKET
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF SUPPLIERS
           5.8.4 BARGAINING POWER OF BUYERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 REGULATORY ANALYSIS 
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                                TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
                    5.9.1.2 Canada
                                TABLE 6 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.9.2 EUROPE
           5.9.3 ASIA PACIFIC
                    5.9.3.1 Japan
                                TABLE 7 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
                    5.9.3.2 China
                                TABLE 8 CHINA: CLASSIFICATION OF MEDICAL DEVICES
                    5.9.3.3 India
    5.10 TRADE ANALYSIS 
           TABLE 9 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018–2022 (USD MILLION)
           TABLE 10 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018–2022 (USD MILLION)
    5.11 TECHNOLOGY ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 
           TABLE 11 MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2023–2024
    5.13 TRENDS/DISRUPTIONS IMPACTING BUSINESSES 
           5.13.1 REVENUE SHIFT IN METABOLISM ASSAYS
    5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
                     TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
           5.14.2 BUYING CRITERIA
                     FIGURE 26 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
                     TABLE 13 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
 
6 METABOLISM ASSAYS MARKET, BY PRODUCT (Page No. - 72)
    6.1 INTRODUCTION 
          TABLE 14 METABOLISM ASSAYS INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 ASSAY KITS & REAGENTS 
           6.2.1 COST-EFFECTIVENESS TO INCREASE ADOPTION IN DRUG DISCOVERY
                    TABLE 15 ASSAY KITS AVAILABLE IN MARKET
                    TABLE 16 MARKET: ASSAY KITS & REAGENTS, BY REGION,  2021–2028 (USD MILLION)
    6.3 INSTRUMENTS & ANALYZERS 
           6.3.1 AUTOMATION IN INSTRUMENTS, ALONG WITH ADOPTION OF SOFTWARE, TO DRIVE SEGMENTAL GROWTH
                    TABLE 17 INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
                    TABLE 18 MARKET: INSTRUMENTS & ANALYZERS, BY REGION,  2021–2028 (USD MILLION)
 
7 METABOLISM ASSAYS MARKET, BY TECHNOLOGY (Page No. - 77)
    7.1 INTRODUCTION 
          TABLE 19 METABOLISM ASSAYS INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 COLORIMETRY 
           7.2.1 COST-EFFECTIVENESS TO DRIVE MARKET
                    TABLE 20 MARKET FOR COLORIMETRY, BY REGION,  2021–2028 (USD MILLION)
    7.3 FLUORIMETRY 
           7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO DRIVE MARKET
                    TABLE 21 MARKET FOR FLUORIMETRY, BY REGION,  2021–2028 (USD MILLION)
    7.4 SPECTROMETRY 
           7.4.1 INCREASED IMPORTANCE IN RESEARCH AND CLINICAL DIAGNOSTICS TO DRIVE MARKET
                    TABLE 22 MARKET FOR SPECTROMETRY, BY REGION,  2021–2028 (USD MILLION)
 
8 METABOLISM ASSAYS MARKET, BY APPLICATION (Page No. - 82)
    8.1 INTRODUCTION 
          TABLE 23 METABOLISM ASSAYS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 DIAGNOSTICS 
           8.2.1 GROWING PREVALENCE OF METABOLIC AND CHRONIC DISEASES TO DRIVE MARKET
                    TABLE 24 DIAGNOSTICS: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 25 MARKET FOR DIAGNOSTICS, BY REGION,  2021–2028 (USD MILLION)
           8.2.2 DIABETES
                    TABLE 26 DIAGNOSTICS: MARKET FOR DIABETES, BY REGION,  2021–2028 (USD MILLION)
           8.2.3 OBESITY
                    TABLE 27 DIAGNOSTICS: MARKET FOR OBESITY, BY REGION,  2021–2028 (USD MILLION)
           8.2.4 CANCER
                    TABLE 28 DIAGNOSTICS: MARKET FOR CANCER, BY REGION,  2021–2028 (USD MILLION)
           8.2.5 CARDIOVASCULAR DISEASES
                    TABLE 29 DIAGNOSTICS: MARKET FOR CARDIOVASCULAR DISEASES,  BY REGION, 2021–2028 (USD MILLION)
           8.2.6 OTHER DIAGNOSTICS
                    TABLE 30 DIAGNOSTICS: MARKET FOR OTHER DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
    8.3 RESEARCH 
           8.3.1 INCREASE IN AWARENESS OF METABOLISM ASSAY IN DISEASE RESEARCH
                    TABLE 31 RESEARCH: MARKET, BY REGION, 2021–2028 (USD MILLION)
 
9 METABOLISM ASSAYS MARKET, BY END USER (Page No. - 91)
    9.1 INTRODUCTION 
          TABLE 32 METABOLISM ASSAYS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 HOSPITALS 
           9.2.1 AFFORDABILITY AND CONVENIENCE TO DRIVE SEGMENT
                    TABLE 33 MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
    9.3 DIAGNOSTIC LABORATORIES 
           9.3.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
                    TABLE 34 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION,  2021–2028 (USD MILLION)
    9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES 
           9.4.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
                    TABLE 35 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
 
10 METABOLISM ASSAYS MARKET, BY REGION (Page No. - 96)
     10.1 INTRODUCTION 
             TABLE 36 METABOLISM ASSAYS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 27 NORTH AMERICA: MARKET SNAPSHOT
             TABLE 37 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 38 NORTH AMERICA: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             TABLE 39 NORTH AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 40 NORTH AMERICA: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 41 NORTH AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.2.1 RECESSION IMPACT
             10.2.2 US
                        10.2.2.1 High rate of drug discovery and toxicity testing to drive market
                                      TABLE 42 US: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 43 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 44 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 45 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 High prevalence of obesity to fuel market growth
                                      TABLE 46 CANADA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 47 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 48 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 49 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             TABLE 50 EUROPE: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 51 EUROPE: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             TABLE 52 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 53 EUROPE: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 54 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 RECESSION IMPACT
             10.3.2 GERMANY
                        10.3.2.1 Growth of pharmaceutical companies to drive market
                                      TABLE 55 GERMANY: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 56 GERMANY: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 57 GERMANY: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 58 GERMANY: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Growing cancer research funding to drive market
                                      TABLE 59 UK: METABOLISM ASSAYS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 60 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 61 UK: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 62 UK: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Rising obese population and prevalence of metabolic disorders to drive market
                                      TABLE 63 FRANCE: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 64 FRANCE: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 65 FRANCE: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 66 FRANCE: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Increasing prevalence of aging population and diabetes to drive market
                                      TABLE 67 SPAIN: METABOLISM ASSAYS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 68 SPAIN: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 69 SPAIN: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 70 SPAIN: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.3.6 ITALY
                        10.3.6.1 Growth of pharmaceutical industry to boost market
                                      TABLE 71 ITALY: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 72 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 73 ITALY: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 74 ITALY: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 75 REST OF EUROPE: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 76 REST OF EUROPE: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 77 REST OF EUROPE: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 78 REST OF EUROPE: MARKET,  BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 28 ASIA PACIFIC: MARKET SNAPSHOT
             10.4.1 RECESSION IMPACT
                        TABLE 79 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 80 ASIA PACIFIC: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 81 ASIA PACIFIC: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 82 ASIA PACIFIC: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 83 ASIA PACIFIC: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Government initiatives to drive market
                                      TABLE 84 JAPAN: METABOLISM ASSAYS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 85 JAPAN: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 86 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 87 JAPAN: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Increasing health awareness to drive demand
                                      TABLE 88 CHINA: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 89 CHINA: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 90 CHINA: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 91 CHINA: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Prevalence of chronic diseases to fuel demand
                                      TABLE 92 INDIA: METABOLISM ASSAYS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 93 INDIA: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 94 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 95 INDIA: MARKET,  BY END USER, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        TABLE 96 REST OF ASIA PACIFIC: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 97 REST OF ASIA PACIFIC: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 98 REST OF ASIA PACIFIC: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 99 REST OF ASIA PACIFIC: MARKET,  BY END USER, 2021–2028 (USD MILLION)
     10.5 REST OF THE WORLD 
             10.5.1 RECESSION IMPACT
                        TABLE 100 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 101 REST OF THE WORLD: MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 102 REST OF THE WORLD: MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 103 REST OF THE WORLD: MARKET,  BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 138)
     11.1 OVERVIEW 
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MARKET
     11.4 MARKET RANKING ANALYSIS 
             FIGURE 30 METABOLISM ASSAYS INDUSTRY RANKING ANALYSIS, BY KEY PLAYER (2022)
     11.5 COMPANY EVALUATION QUADRANT (2022) 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 31 METABOLISM ASSAYS INDUSTRY: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
     11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022) 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 32 METABOLISM ASSAY MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
     11.7 COMPETITIVE BENCHMARKING 
             TABLE 105 METABOLISM ASSAYS INDUSTRY: COMPETITIVE BENCHMARKING OF KEY PLAYERS
             TABLE 106 PRODUCT FOOTPRINT OF KEY PLAYERS
             TABLE 107 REGIONAL FOOTPRINT OF KEY PLAYERS
             TABLE 108 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
     11.8 COMPETITIVE SCENARIO 
             11.8.1 PRODUCT LAUNCHES
                        TABLE 109 PRODUCT LAUNCHES, JANUARY 2020–AUGUST 2023
             11.8.2 DEALS
                        TABLE 110 DEALS, JANUARY 2020–AUGUST 2023
             11.8.3 OTHER DEVELOPMENTS
                        TABLE 111 OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2023
 
12 COMPANY PROFILES (Page No. - 149)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 THERMO FISHER SCIENTIFIC INC.
                        TABLE 112 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
             12.1.2 MERCK KGAA
                        TABLE 113 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
             12.1.3 ABCAM PLC.
                        TABLE 114 ABCAM PLC.: BUSINESS OVERVIEW
                        FIGURE 35 ABCAM PLC.: COMPANY SNAPSHOT (2022)
                        TABLE 115 ABCAM PLC.: DEALS
             12.1.4 AGILENT TECHNOLOGIES INC.
                        TABLE 116 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
                        FIGURE 36 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)
                        TABLE 117 AGILENT TECHNOLOGIES INC.: PRODUCT LAUNCHES
             12.1.5 KANEKA EUROGENTEC S.A.
                        TABLE 118 KANEKA EUROGENTEC S.A.: BUSINESS OVERVIEW
                        FIGURE 37 KANEKA EUROGENTEC S.A.: COMPANY SNAPSHOT (2022)
             12.1.6 SARTORIUS AG
                        TABLE 119 SARTORIUS AG: BUSINESS OVERVIEW
                        FIGURE 38 SARTORIUS AG: COMPANY SNAPSHOT (2022)
                        TABLE 120 SARTORIUS AG: PRODUCT LAUNCHES
             12.1.7 PROMEGA CORPORATION
                        TABLE 121 PROMEGA CORPORATION: BUSINESS OVERVIEW
             12.1.8 ELABSCIENCE BIOTECHNOLOGY INC.
                        TABLE 122 ELABSCIENCE BIOTECHNOLOGY INC.: BUSINESS OVERVIEW
             12.1.9 RAYBIOTECH LIFE, INC.
                        TABLE 123 RAYBIOTECH LIFE, INC.: BUSINESS OVERVIEW
             12.1.10 BMG LABTECH
                        TABLE 124 BMG LABTECH: BUSINESS OVERVIEW
                        TABLE 125 BMG LABTECH: PRODUCT LAUNCHES
             12.1.11 BIOTREND CHEMIKALIEN GMBH
                        TABLE 126 BIOTREND CHEMIKALIEN GMBH: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 3H BIOMEDICAL AB
             12.2.2 BIOASSAY SYSTEMS
             12.2.3 EMELCA BIOSCIENCE
             12.2.4 CREATIVE BIOARRAY
             12.2.5 TEMPO BIOSCIENCE, INC.
             12.2.6 NCARDIA
             12.2.7 NOVOCIB
             12.2.8 ETON BIOSCIENCE, INC.
             12.2.9 CAYMAN CHEMICAL COMPANY
             12.2.10 ENZO LIFE SCIENCES, INC.
             12.2.11 ABNOVA CORPORATION
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 185)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the metabolism assays market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the metabolism assays market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the metabolism assays market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospitals, clinics, fitness centers, home users, and academic & research institutes) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing, and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Breakdown of Primary Participants:

Metabolism Assays Market Size, and Share

Note 1: *Others include sales managers, marketing managers, and product managers.

Note 2: Tiers are defined based on a company’s total revenue as of 2022: Tier 1=> USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3=< USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

All major product manufacturers offering various metabolism assays were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value metabolism assays market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of metabolism assays market at the regional and country-level 
  • Relative adoption pattern of each metabolism assays market among key application segments at the regional and/or country-level 
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level. 
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level 

Global Metabolism assays Market Size: Top Down Approach

Metabolism Assays Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Metabolism assays Market Size: Bottom-Up Approach.

Metabolism Assays Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Metabolism assays industry.

Market Definition

Metabolic assay is used to identify metabolic stability in chemical structures in connection with hepatic metabolism. It evaluates the rate of clearance of a drug using the liver hepatocytes or microsomes. The disappearance of the parent chemical with time is an example of a change. Metabolism assay is available in comprehensive packages equipped with the essential components and detailed protocols required to investigate specific facets of cellular metabolism. These kits offer researchers a convenient and standardized approach to explore and understand metabolic processes accurately, efficiently, and consistently.

Key Stakeholders

  • Senior Management
  • Finance/Procurement Department
  • Pathologist/Researchers/Technician

Report Objectives

  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To define, describe, segment, and forecast the metabolism assays market by product, technology, application, end-user, and region
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall metabolism assay market
  • To forecast the size of the metabolism assays market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Rest of the world.
  • To profile key players in the metabolism assays market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as acquisitions; product launches; expansions; collaborations, agreements, & partnerships; and R&D activities of the leading players in the metabolism assays market.
  • To benchmark players within the metabolism assays market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

MarketsandMarkets offers the following customizations for this market report:

Additional country-level analysis of the Metabolism assays market

Profiling of additional market players (up to 5)

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the Metabolism assays Market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
MD 8799
Published ON
Sep, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Metabolism Assays Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback